What is the recommended Polymyxin B dosing regimen for treating pneumonia, including loading and maintenance doses?

Polymyxin B Dosing for Pneumonia

For pneumonia caused by multidrug-resistant Gram-negative bacteria, administer polymyxin B with a loading dose of 2–2.5 mg/kg followed by a maintenance dose of 1.5–3 mg/kg/day divided into 2 doses every 12 hours. This weight-based dosing strategy is supported by international consensus guidelines and optimizes early therapeutic concentrations while minimizing nephrotoxicity 1.

Loading Dose Rationale

The loading dose is critical to achieve optimal plasma levels on the first day of therapy. Unlike colistin (which is administered as an inactive prodrug), polymyxin B is given as the active drug and reaches therapeutic concentrations more rapidly 1. The 2–2.5 mg/kg loading dose should be administered to all patients regardless of renal function, as polymyxin B clearance is not significantly influenced by kidney dysfunction 1.

Maintenance Dosing Strategy

The maintenance dose of 1.5–3 mg/kg/day should be divided into two doses given every 12 hours 1, 2. More recent evidence suggests that:

• For patients weighing 50–90 kg, a fixed-dose strategy may be preferable: 150 mg loading dose followed by 75 mg every 12 hours 3
• This fixed-dose approach may reduce nephrotoxicity risk compared to weight-based dosing while maintaining efficacy 3
• The 2016 IDSA/ATS guidelines recommend 2.5–3.0 mg/kg/day divided in 2 daily doses for ventilator-associated pneumonia 2

Renal Adjustment Considerations

No dose adjustment is necessary for patients on continuous renal replacement therapy (CRRT) 1. This represents a significant advantage over colistin, which requires complex dose modifications based on creatinine clearance. Polymyxin B dosing is calculated based on body weight, and plasma concentrations are not influenced by renal function 1.

Combination Therapy vs. Monotherapy

Polymyxin B should be used in combination with another active antimicrobial agent rather than as monotherapy for severe pneumonia 4. The 2023 Chinese guidelines strongly recommend polymyxin combination therapy over monotherapy for carbapenem-resistant Gram-negative bacterial infections (strong recommendation, moderate-quality evidence) 4. Combination therapy reduces treatment failure rates and improves pathogen eradication without significantly increasing nephrotoxicity 4.

Adjunctive Inhaled Polymyxin B

For patients with ventilator-associated pneumonia who cannot achieve target concentrations with intravenous administration alone, add inhaled polymyxin B 25–50 mg every 12 hours 5, 6, 7. The combined intravenous plus inhaled (IV+IH) regimen demonstrates:

• Significantly lower overall mortality compared to IV alone (OR 0.67,95% CI 0.50–0.88) 7
• Higher clinical success rates (OR 1.90,95% CI 1.20–3.00) 7
• Better microbial eradication (OR 2.70,95% CI 1.90–3.90) 7
• Polymyxin B concentrations in epithelial lining fluid reach 20.6–97.6 mg/L with aerosol delivery, far exceeding plasma levels 5

Practical Dosing Algorithm

1. Calculate loading dose: 2–2.5 mg/kg of total body weight (or fixed 150 mg for 50–90 kg patients)
2. Administer maintenance dose 12 hours after loading dose: 1.5–3 mg/kg/day divided Q12h (or fixed 75 mg Q12h)
3. No adjustment needed for renal dysfunction or CRRT
4. Always combine with another active antimicrobial (e.g., carbapenem if MIC permits, sulbactam, or tigecycline)
5. Consider adding inhaled polymyxin B if:
   • Ventilator-associated pneumonia
   • High MIC values (>1 mg/L)
   • Inadequate clinical response after 48–72 hours

Safety Monitoring

Monitor renal function during treatment, as nephrotoxicity remains the primary concern 1. However, polymyxin B demonstrates lower incidence of renal failure compared to colistin 1. Therapeutic drug monitoring should be performed where available 4. Avoid concurrent use of other nephrotoxic or ototoxic agents 4.

Critical Pitfalls to Avoid

• Do not use weight-based dosing exceeding 3 mg/kg/day, as recent real-world data suggest lower doses (<1.5 mg/kg/day) may be associated with lower mortality and better safety profiles 8, 9
• Do not omit the loading dose—suboptimal concentrations in the first 2–3 days are associated with treatment failure 1
• Do not use polymyxin B as monotherapy for severe pneumonia—combination therapy significantly improves outcomes 4
• Do not adjust doses for renal dysfunction as you would with colistin—polymyxin B clearance is independent of kidney function 1